ArticleNature communications2025
Orchestrating intratumoral DC-T cell immunity for enhanced tumor control via radiotherapy-activated TLR7/8 prodrugs in mice.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- TIR domain proteins: regulatory mechanisms in the tumor immune microenvironment, clinical translation strategies, and prospects for precision therapy applications.Frontiers in immunology · 2025Pooled it
- Low-dose radiotherapy as an immunomodulator in cancer: dose-specific mechanisms and hybrid high-dose/low-dose strategies.Biomarker research · 2026Review
- Challenges and opportunities in combining radiotherapy and immunotherapy for localized pancreatic cancer.Nature reviews. Gastroenterology & hepatology · 2026Review
- Cancer-associated adipocytes: metabolic reprogramming, crosstalk and therapeutic implications in tumor progression.Signal transduction and targeted therapy · 2026Review
- Timing matters: how mechanism-guided sequencing shapes the efficacy of radiotherapy-immunotherapy combinations : A systematic review.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Review
- A new perspective on cancer treatment: the interaction and application prospect between ICIs and radiotherapy.Precision radiation oncology · 2026Review
- Review
- Liposome-Encapsulated Carfilzomib as a Radiosensitizer in Solid Tumors.Molecular pharmaceutics · 2026Article
- Opportunities and challenges of targeting cGAS-STING in cancer.Nature reviews. Cancer · 2026Review
- Piezo1 as a mechanical checkpoint in T cell immunotherapy for solid tumors.Frontiers in pharmacology · 2026Review
- Targeting innate immunity in cancer: mechanistic foundations, therapeutic vaccination, and clinical translation.Frontiers in immunology · 2026Review
- The role of ionizing radiation-initiated reactions in targeted activation of chemotherapeutics.Nature reviews. Chemistry · 2026Review
- Targeting the SOX9/TIMP1 Axis with iRGD-Conjugated Nanoplatform Enhances Dendritic Cell Function and Photodynamic Immunotherapy in Gastric Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Single atom engineering for radiotherapy-activated immune agonist prodrugs.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Optimizing intratumoral dendritic cell (DC)-T cell responses is pivotal for effective cancer immunotherapy. However, the mechanistic governing these dynamics within the tumor microenvironment (TME) remains unclear, and strategies to improve their therapeutic potential are underexplored. Here, we show that precise radiotherapy activates the pro-TLR7/8 agonist imidazoquinoline (IMDQ) locally in preclinical tumor models, stimulating DCs to elicit T cell immunity without the need for further recruitment or causing systemic toxicity. Mechanistically, this synergistic approach triggers type I interferon via STING and MyD88 signaling pathways, strengthening local immune responses. Importantly, we reveal that fractionated, low-dose radiotherapy can effectively optimize local DC-T cell dynamics to control the irradiated tumor, while also promoting abscopal effect. Thus, our findings underscore the critical role of harnessing intratumoral DCs to reinvigorate pre-existing T cell immunity and provide mechanistic insights into improving both local and distal tumor control, opening new avenues for advancing cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.